New stock news | Plais Pharmaceuticals submits application to Hong Kong Stock Exchange.

According to the disclosure from the Hong Kong Stock Exchange on February 13th, Plaie Pharmaceuticals (Jiangsu) Co., Ltd. (referred to as Plaie Pharmaceuticals) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CITIC SEC as its exclusive sponsor. The prospectus shows that Plaie Pharmaceuticals is a leading innovative antimicrobial peptide (AMP) therapy company established in April 2009, focusing on four core therapeutic areas: anti-infection, metabolic diseases, tumors, and autoimmune diseases. The company is committed to addressing global unmet health needs through its proprietary breakthrough technology and candidate drugs. As of the last practicable date, Plaie Pharmaceuticals has nine candidate drugs, including a core product (PL-5) and two main products (PL-3301 and PL-18).